arrow
K

Kelli M. Wilson

national center for advancing translational sciences
H指数:23
被引数:2,401

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma

治疗性NAMPT抑制揭示了神经母细胞瘤中可靶向的代谢易损性

2026-08-050
OAAI
Induced pluripotent stem cell–derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities

诱导多能干细胞来源的恶性神经鞘瘤进展模型模拟胶质细胞向神经间充质过渡并揭示治疗机会

2026-06-170
OAAI
An Assessment of Kinase Selectivity; Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors

对激酶选择性的评估;几种布鲁顿酪氨酸激酶(BTK)抑制剂的酶抑制动力学及体外活性

2025-11-180
OAAI
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon

弥漫性半球神经胶质瘤,H3 G34-mutant疾病发展,DNA修复,微环境和治疗方法的综述

2025-08-140
OAAI
Multi- Component, Time- Course screening to develop combination cancer therapies based on synergistic toxicity

多组分,时程筛选,以开发基于协同毒性的联合癌症疗法

2024-11-250
PRE
Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia
2024-10-231
OAAI
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
2024-10-120
PRE
Methotrexate-based PROTACs as DHFR-specific chemical probes
2024-02-014
OAAI
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma
2023-08-012
PRE
A landscape of response to drug combinations in non-small cell lung cancer
2023-06-2814
OAAI
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCAmutant ovarian cancer
2023-06-2112
OA